Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

7-day Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children From Birth to Less Than 6 Months With Arterial or Venous Thrombosis

Trial Profile

7-day Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children From Birth to Less Than 6 Months With Arterial or Venous Thrombosis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Arterial thrombosis; Catheter thrombosis; Venous thromboembolism; Venous thrombosis
  • Focus Pharmacodynamics; Pharmacokinetics; Registrational
  • Acronyms EINSTEIN; Einstein Jr
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 20 Dec 2021 According to a Janssen Pharmaceuticals media release, based on the EINSTEIN-Jr and UNIVERSE studies, the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO: the treatment of venous thromboembolism and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after initial parenteral anticoagulant treatment; and thromboprophylaxis in children aged 2 years and older with congenital heart disease who have undergone Fontan procecedure
    • 22 Jan 2021 According to a Bayer media release, the Ministry of Health, Labor and Welfare in Japan has approved the use of the oral Factor Xa inhibitor rivaroxaban (Xarelto) to treat VTE and prevent VTE recurrence in children, including catheter related thrombosis, cerebral vein and sinus thrombosis. The approval is based on data from a comprehensive clinical program, including the phase III EINSTEIN-Jr. study.
    • 13 Nov 2020 Results presented in a Bayer media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top